PT  - JOURNAL ARTICLE
AU  - Seaman, Michael S.
AU  - Siedner, Mark J.
AU  - Boucau, Julie
AU  - Lavine, Christy L.
AU  - Ghantous, Fadi
AU  - Liew, May Y.
AU  - Mathews, Josh
AU  - Singh, Arshdeep
AU  - Marino, Caitlin
AU  - Regan, James
AU  - Uddin, Rockib
AU  - Choudhary, Manish C.
AU  - Flynn, James P.
AU  - Chen, Geoffrey
AU  - Stuckwisch, Ashley M.
AU  - Lipiner, Taryn
AU  - Kittilson, Autumn
AU  - Melberg, Meghan
AU  - Gilbert, Rebecca F.
AU  - Reynolds, Zahra
AU  - Iyer, Surabhi L.
AU  - Chamberlin, Grace C.
AU  - Vyas, Tammy D.
AU  - Vyas, Jatin M.
AU  - Goldberg, Marcia B.
AU  - Luban, Jeremy
AU  - Li, Jonathan Z.
AU  - Barczak, Amy K.
AU  - Lemieux, Jacob E.
TI  - Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses
AID  - 10.1101/2022.03.02.22271731
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.02.22271731
4099  - http://medrxiv.org/content/early/2022/03/03/2022.03.02.22271731.short
4100  - http://medrxiv.org/content/early/2022/03/03/2022.03.02.22271731.full
AB  - There is increasing evidence that the risk of SARS-CoV-2 infection among vaccinated individuals is variant-specific, suggesting that protective immunity against SARS-CoV-2 may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. For individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Massachusetts Consortium for Pathogen ReadinessAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Mass General Brigham institutional review board under protocol 2021P000812I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data were submitted to Genbank under accession number PRJNA759255